Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sartorius Stedim Biotech SA | EU:DIM | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 6.40 | 3.80% | 175.00 | 173.50 | 176.50 | 177.10 | 169.60 | 169.60 | 62,661 | 16:40:00 |
From Nov 2022 to Nov 2024
By Cecilia Butini
Shares in German pharmaceutical and laboratory equipment supplier Sartorius AG and its France-listed subsidiary Sartorius Stedim Biotech SA fell in opening trade on Friday after the company announced its acquisition of Polyplus for about 2.4 billion euros ($2.62 billion).
Sartorius said it would receive a bridge loan facility from J.P. Morgan for a transitional period to finance the transaction, and that it would refinance the loan with long-term financing instruments which might also include an equity component.
At 0745 GMT, Sartorius shares traded down 5.6% at EUR386.40. Sartorius Stedim traded down 6.8% at EUR287.90
Polyplus produces key components in the production of viral vectors used in cell and gene therapies and other advanced medicinal therapeutic products, according to Sartorius. It is expected to generate sales revenue in the upper double-digit million euro range, and a very substantial Ebitda margin in 2023, the company said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
March 31, 2023 04:10 ET (08:10 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Sartorius Stedim Biotech Chart |
1 Month Sartorius Stedim Biotech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
